BackgroundNot much is known about the burden of generalized pustular psoriasis (GPP).ObjectivesTo document the burden of GPP in Canada and to compare it with psoriasis vulgaris (PV).MethodsNational data were used to identify Canadian adult patients with GPP or PV hospitalized or visiting an emergency department (ED) or hospital-/community-based clinic between April 1, 2007, and March 31, 2020. Analyses of 10-year prevalence and 3-year incidence were conducted. Costs were determined when the most responsible diagnosis (MRD) was GPP or PV (MRD costs) and for all reasons (all-cause costs).ResultsIn the prevalence analysis, 10-year mean (SD) MRD costs were $2393 ($11,410) for patients with GPP and $222 ($1828) for those with PV (P< .01). In the incidence analysis, patients with GPP had higher 3-year mean (SD) MRD costs ($3477 [$14,979] vs $503 [$2267] for PV;P< .01). Higher all-cause costs were also associated with patients with GPP. Inpatient/ED mortality was higher in the GPP group in our 10-year prevalence (9.2% for patients with GPP vs 7.3% for those with PV;P= .01) and 3-year incidence (5.2% for patients with GPP and 2.1% for those with PV;P= .03) analyses.LimitationsPhysician and prescription drug data were not available.ConclusionPatients with GPP incurred higher costs and mortality than patients with PV.